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Abstract
Systemic immune stimulation has been associated with
increased risk of myeloid malignancies, but the pathogenic link
is unknown.We demonstrate in animalmodels that experimental
systemic immune activation alters the bone marrow stromal
microenvironment, disarranging extracellular matrix (ECM)
microarchitecture, with downregulation of secreted protein acidic
and rich in cysteine (SPARC) and collagen-I and induction of
complement activation. These changes were accompanied by a
decrease in Treg frequency and by an increase in activated effector
T cells. Under these conditions, hematopoietic precursors har-
boring nucleophosmin-1 (NPM1) mutation generated myeloid
cells unﬁt for normal hematopoiesis but prone to immunogenic
death, leading to neutrophil extracellular trap (NET) formation.
NET fostered the progression of the indolent NPM1-driven mye-
loproliferation toward an exacerbated and proliferative dysplastic
phenotype. Enrichment in NET structures was found in the bone
marrow of patients with autoimmune disorders and in NPM1-
mutated acute myelogenous leukemia (AML) patients. Genes
involved in NET formation in the animal model were used to
design a NET-related inﬂammatory gene signature for human
myeloid malignancies. This signature identiﬁed two AML subsets
with different genetic complexity and different enrichment
in NPM1 mutation and predicted the response to immunomod-
ulatory drugs. Our results indicate that stromal/ECM changes and
priming of bone marrow NETosis by systemic inﬂammatory
conditions can complement genetic and epigenetic events
towards thedevelopmentandprogressionofmyeloidmalignancy.
Cancer Res; 77(13); 3685–99. 2017 AACR.
Introduction
Alterations in the bone marrow osteoblastic and vascular
niches that nurture hematopoietic stem cells (HSC) are associated
with the outgrowth of myeloid cells within a biased leukemic
niche (1, 2). Such alterations encompass the adaptationof speciﬁc
mesenchymal cell populations and the disruption of normal
gradients in structural and secreted proteins, including matricel-
lular proteins, cytokines, and chemokines (3). A key regulator of
bone marrow stromal changes is the secreted protein acidic and
rich in cysteine (SPARC; ref. 4), a matricellular protein in which
up- and downregulation has been associated with hematologic
neoplasms (2, 5).
Along with remodeling of the bone marrow mesenchymal
architecture, myeloid clone expansion changes the cytokine
proﬁle of the hematopoietic milieu. Increased levels of proin-
ﬂammatory cytokines including TNF, IL6, and IL8 have been
reported in patients with myeloproliferative neoplasms, mye-
lodysplastic syndromes (MDS), and myeloid leukemia with an
unfavorable predicted disease course (6, 7). The induction of
an inﬂammatory state in the myelopoietic parenchyma is
mutually linked with the status of the stromal architecture. A
defective ECM organization resulting from SPARC deﬁciency
favors the over-activation of myeloid cells (8) and granulocyte
immunogenic death via the formation of neutrophil extracel-
lular traps (NET; ref. 5). NETotic death is characterized by the
expression of IFN response-related transcriptional programs
associated with the induction of inﬂammation and exacerba-
tion of autoimmune disease, in which NETs contribute as
sources of autoantigens and costimulatory signals (9–13). A
link has been demonstrated between dysregulated immune
stimulation and the occurrence of myeloid malignancies.
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Figure 1.
Chronic immune stimulation induces stromal changes in the bone marrow (BM). A, Schematic representation of NET-loaded DC-based immunization protocol.
B,Quantiﬁcation of anti-dsDNAautoantibodies andMPO-ANCA levels in immunized and controlmice. Data are expressed asU/mLof IgG for anti-dsDNAor as ng/mL
of IgG for MPO-ANCA (n ¼ 10/each group;  , P < 0.001, Mann–Whitney test). C, Expression of Sparc and Col1a1 in total bone marrow cells isolated from
immunized and control mice. The fold change in the expression of the target genes relative to the internal control gene (GAPDH) is shown (n ¼ 5;  , P < 0.05,
Mann–Whitney test). D, Representative IHC analysis of type I collagen and SPARC shows the reduction of both ECM molecules in the bone marrow of
immunizedmice. Scale bars, 50 mm. E,Quantitative analysis of collagen type I and SPARC in immunoﬂuorescence images as detailed in the Supplementary Methods.
(Continued on the following page.)
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Large-scale epidemiologic studies have shown that the history
of chronic autoinﬂammatory or autoimmune diseases is cor-
related with increased incidence of MDS or acute myeloid
leukemia (AML; ref. 14); however, the role of systemic immune
activation in the pathobiology of myeloid malignancies
remains unknown. The highest risk of development of MDS
and AML has been reported in patients with autoimmune
diseases in which NETs have a recognized pathogenic role, for
example, systemic lupus erythematosus and antineutrophil
cytoplasmic antibody (ANCA)-related vasculitis (9, 15).
In this study, we investigated whether a persistent immune
stimulation can change the bone marrow stromal microenviron-
ment and affect hematopoietic precursor proliferation. We iden-
tiﬁed a novel regulation of myeloid cell expansion involving the
crosstalk between the immune cells and stromal components of
the bone marrow microenvironment. Such crosstalk is proposed
to be relevant in explaining the link between systemic immune
activation and myeloid neoplasms.
Materials and Methods
Mice
hMPR8-NPMcþ transgenic mice (B6. Tg<hMRP8-NPMc>
Ptprc<b>tg/J), hereafter referred as NPMc, were obtained by back-
crossing (C57BL/6J  CBA) F1-hMRP8-NPMc mice to C57BL/6
(B6. Ptprc<b>). The bone marrow of Trif–/– mice was kindly
provided by Dr. Garlanda (Humanitas Clinical and Research
Center,Milan, Italy). All experiments involving animals described
in this study were approved by the Ministry of Health (authori-
zation number 10/11). The protocol describing the immuniza-
tion of WT and NPMcmice with NET-loaded DCs is described in
the Supplementary Data.
Human and murine bone marrow histology,
immunohistochemistry, and immunoﬂuorescence
Histologic, histochemical, and immunoﬂuorescence analyses
of murine and human bone marrow samples were performed as
previously described (2, 5) and detailed in the Supplementary
Data. For in situ histopathologic analyses of human bonemarrow
specimens, the bone marrow biopsies from 12 patients with
autoimmunity-associated peripheral cytopenias were selected
from the archives of the Department of Hematology, University
of Foggia, Foggia, Italy, and the Department of Health Sciences,
University of Palermo, Palermo, Italy. Patient characteristics are
listed in Supplementary Table S1.
Bone marrow and spleen FACS analysis of
hematopoietic precursors
Brieﬂy marrow and spleen cell suspensions were stained
with a pool of antibodies for Lin positive markers, including
CD3, CD11b, CD45R, Ly6G, CD4, CD8, and Ter-119, and stem
cell and progenitor cell markers, including CD117 (c-Kit),
CD34, and CD16/CD32. Progenitors were identiﬁed according
to their expression of CD34 and CD16/CD32 within the gate
of Lin–CD117þ cells. Bone marrow, spleens, and PBL samples
were also evaluated for granulocyte enrichment by staining
cell suspensions with mAbs against CD11b, Ly6G, and CD45,
followed by FACS analysis. All antibodies were purchased
from eBioscience. Samples were acquired on an LSR II (BD
Biosciences).
Immunization of WT and NPMc preleukemic mice with
NET-loaded dendritic cells
Inﬂammatory PMNs (IFNg/TNF-treated), prone to dye of
NETosis, were obtained from agar plugs subcutaneously injected
into C57BL/6 mice, as previously described (9). In particular,
PMN were seeded onto coated tissue culture dishes in IMDM 2%
FCS, allowed to adhere for 30 minutes and added with myeloid
dendritic cell (mDC; 1:1; PMN:DC) for 16 hours. During this
period NETs are induced and transfer their component to mDCs
(9). Dendritic cell (DC) were isolated from the coculture via
positive selection, counted and injected intraperitoneally (2.5–
5  106 cells, once a week for a total of six injections) into na€ve
mice. Three months after the last immunization, mice underwent
a boosting immunization. Autoimmunity was evaluated starting
1 month after the boost by measuring the titer of ANCA and
dsDNA autoantibodies using speciﬁc ELISA kits (MPO-ANCA
IgG, ELISA Kit from Cusabio and mouse anti-dsDNA antibody
ELISA Kit from Alpha Diagnostic International).
Qualitative and quantitative evaluation of NET formation
For ex vivo isolated neutrophils, spontaneous NETosis was
evaluated by seeding bone marrow-derived PMNs onto poly-D-
lysine–coated glasses in 2% FCS-IMDM in presence or absence of
PMA (16). To quantify NETosis and to distinguish NETosis from
apoptosis, the cell-impermeable DNA dye Sytox green, was added
to PMNs such tomeasure the size of the released nuclear contents
from micrographs using the software-assisted technique, accord-
ing toMetzler and colleagues (17). To assessNET formation in vivo
in murine and human bone marrow biopsies, confocal micros-
copy analysis was performed by staining with mAbs to murine
or human-MPO (from Millipore and Novocastra, respectively)
and anti-Histone H3 (citrulline R2þR8þR17, from Abcam),
followed by staining with Alexa Fluor 546-conjugated goat
anti-rabbit or goat anti-mouse secondary antibodies (Invitro-
gen Molecular Probes). Nuclei were counterstained with Draq5
or Dapi. To evaluate nucleophosmin (NPM) relocalization
onto the NET threads, PMA-induced NETs (obtained from
splenic WT- and NPMc-PMN treated 16 hours with PMA) were
sequentially stained with mAb to nucleophosmin (18) and
MPO (Millipore) or PR3 (Millipore). The NET-DNA was coun-
terstained with Draq5.
In vitro cultures of Lin–c-Kitþ hematopoietic cells
Lin–c-Kitþ cells were FACS-sorted from the bone marrow of
NPMc or controlmice (BD, FACSAria), stainedwith carboxyﬂuor-
escein succinimidyl ester (CFSE) and added to PMNs undergoing
NETosis [inﬂammatory PMNs fromagar plugs (9) or PMA-treated
(Continued.) F, Representative triple confocal microscopy analysis of type I collagen or SPARC, together with CD29 and c-Kit performed on bone marrow sections
from immunized and control mice. The image shows the reduction of type I collagen and SPARC expression in mesenchymal (CD29þ) cells of the osteoblastic
niche that is enriched in hematopoietic (c-Kitþ) hematopoietic precursors. Scale bars, 10 mm. G, IHC of C1q in bone marrow sections from immunized and
control mice showing an increase in vascular (arrows) and stromal (arrowheads) C1q expression in immunized mice. H, Representative double immunoﬂuorescence
analysis showing that the increased C1q induction in the bone marrow of immunized mice is associated with an increase in the stromal deposition of C5a. I,
Quantitative analysis of C1q and C5a in immunoﬂuorescence images as detailed in Supplementary Methods.
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PMNs]. The coculture was performed in StemSpan H3000 medi-
um (Stem Cell Technologies), without adding any other supple-
ment. After 72 hours of coculture, cells are harvested and the c-
Kitþ cell fraction, which comprised c-KitþScaþGR-1– early pro-
genitors, c-KitþSca–GR-1– committed precursors (mostly GMP),
and c-KitþSca–GR-1þmyeloblasts, was analyzed for proliferation.
Proliferation was read out by measuring dilution of the CFSE dye
(19).
Gene expression proﬁle analysis
Gene expression proﬁle (GEP) analysis was performed in a
panel of primary hematopoietic malignancies, including AML
(AN¼100), chronicmyelogenous leukemia (CML,N¼50),MDS
(N ¼ 50), and in a panel of healthy bone marrow samples
(N ¼ 30), which were randomly selected among those included
in a large multicentric GEP study available on GEO database
(GSE13159; refs. 20, 21). We also analyzed 461 AML cases for
which gene expression data and information on theNPM1 status
(mutated vs. wild type) were available (GEO Access: GSE6891;
refs. 22, 23) and 15 AML cases included in a phase II clinical trial
testing the combination of lenalidomide and cytarabine (Len-
Ara) and forwhichour grouppreviously generatedGEP (24). Each
casewas assigned to either group 1 or 2 based on the expression of
the NET-related inﬂammatory signature. A detailed description of
the analysis performed is provided in the Supplementary Data.
Results
Systemic autoimmunity induces modiﬁcations in the bone
marrow stromal and immune cell compartments
To investigate how systemic autoimmunity could affect bone
marrow stroma remodeling, na€ve C57BL/6mice were repeatedly
immunized by intraperitoneal injections of mDC loaded with
NET components (Fig. 1A and Supplementary Data). As previ-
ously shown (9), immunized mice developed serum autoanti-
bodies and ANCA-associated autoimmune vasculitis in the kid-
ney and lung parenchyma (Fig. 1B; Supplementary Fig. S1A and
S1B).Comparedwithna€vemice, the bonemarrowof immunized
mice showed a signiﬁcant decrease in the levels of type I collagen
and SPARC, as assessed by semiquantitative PCR (Fig. 1C), IHC
(Fig. 1D), and in situ immunoﬂuorescence (Supplementary Fig.
S1C). The decrease in type I collagen and SPARC was particularly
evident inCD29þ stromal cells lining the osteoblastic (OB) niche,
which is enriched in c-Kitþprecursors (Fig. 1F).Moreover, stromal
and endothelial bonemarrow cells showed increased C1q expres-
sion, which was associated with C5a (Fig. 1G–I), suggesting
activation of the complement cascade. Finally, a trend in the
induction of P-selectin expression was also observed in the bone
marrow of immunized mice (Supplementary Fig. S1D–S1F).
Foxp3þ Treg cells are typically either depleted or skewed
toward inﬂammatory Th1 or Th17 cells under autoimmune
conditions (25). In the bone marrow of na€ve mice, nearly 30%
of CD4þ T cells were Foxp3þ Treg cells, a frequency much
higher than that of the other lymphoid organs, where Treg cells
accounted for 5% to 15% of total CD4þ T cells (Supplementary
Fig. S1G and S1H). In contrast, in the bone marrow of immu-
nized mice the frequency of Treg cells was signiﬁcantly reduced
(Fig. 2A). Also reduced in this subset was the expression of
OX40 (26), a marker of activation (Fig. 2A). On the contrary,
the expression of CD25 and OX40 on Teff cells was increased
(Fig. 2B) together with their production of IFNg and TNF (Fig.
2C and D). In immunized mice, TNF and IFNg were also
induced in CD45þ cells other than T lymphocytes (Fig. 2E).
To test the existence of a link between the TNF- and IFNg-rich
inﬂammatory milieu and stromal ECMmodiﬁcations, bonemar-
row-MSCs were isolated from the bonemarrow of na€vemice and
stimulated 24 hours with IFNg , TNF, or both. Semiquantitative
PCR analysis showed that these stimuli, mostly when in combi-
nation, signiﬁcantly decrease the expression of col1a1 and Sparc in
bone marrow-MSCs (Fig. 2F and G).
Collectively, these results show that systemic immune activa-
tion modiﬁes the bone marrow stromal microenvironment and
changes the immune cell composition from immune-regulatory
to proinﬂammatory.
Figure 2.
A proinﬂammatory bone marrow microenvironment supports NET formation, thereby promoting hematopoietic precursor proliferation. A, Reduced frequency
of CD4þCD25þFoxp3þ Tregs and their reduction in OX40 ﬁtness marker expression (MFI, mean ﬂuorescent intensity) in bone marrow (BM) of immunized
(gray bar) compared with na€ve (black bar) mice. B, Activation of CD4þFoxp3 Teff upon immunization evaluated in terms of CD25 and OX40 expression. C and D,
Activation of CD4þFoxp3 Teff upon immunization evaluated as IFNg and TNF secretion. The frequency of IFNg- and TNF-secreting cells was evaluated
within the gate of CD4þ and Foxp3 cells as shown in the relative representative gating strategy. E, IFNg and TNF secretion by non-CD4 leukocytes in the bone
marrow of na€ve (black bar) and vaccinated (gray bar) mice. Data are representative of three independent experiments, each including ﬁve mice per groups;
statistical analysis: Student's t test,  ,P<0.05;  ,P<0.01. F andG,Expression ofCol1a and Sparcgenes in bonemarrow-MSC stimulatedor notwith IFNg , TNF, or their
combination. The fold change in expression of the target genes relative to the internal control gene (GAPDH) is shown. H, Ex vivo spontaneous NET formation
by PMNs isolated from the bone marrow of immunized or control mice. Spontaneous NET formation was evaluated by seeding bone marrow–isolated PMNs
into poly-D-lysine–coated glasses in presence of the DNA-dye Sytox green. Scale bars, 10 mm. I, Quantiﬁcation of NET formed by bone marrow-PMNs isolated from
immunized mice. Nuclear area of bone marrow PMN from na€ve and immunized mice is plotted against the percentage of SYTOX-positive cells corresponding to a
given nuclear area. PMN undergoing NETosis are characterized by broad range of nuclear areas, whereas apoptotic neutrophils show smaller nuclear areas.
Quantiﬁcation shows that PMN from immunizedmicemakemore NET in comparison to PMN fromna€vemice. Experiments comparing the two types of bonemarrow
PMN were repeated three times with PMN from at least three donor mice each. Number of nuclei analyzed/experiment ¼ 100. J, Immunoﬂuorescence for MPO
performed on bone marrow sections from immunized and na€ve mice showing the presence of extracellular MPO threads, which is associated with NET
formation (arrows), in bone marrow sections from immunized mice. In na€ve mice, MPO staining was conﬁned to the cytoplasmic area of myeloid cells. Scale bars,
50 mm. K, Representative confocal microscopy analysis showing the colocalization of citrullinated histone H3, MPO, and DAPI in extracellular traps of bone marrow
from immunizedmice. Scale bars, 10mm. L,Todetermine the role ofNET in hematopoietic precursor proliferation, FACS-sorted c-kitþbonemarrow cellswere stained
with the proliferation dye CFSE and cocultured with NET. The proliferative effect of NETs was analyzed in the different fractions of c-Kitþ hematopoietic cells
(see Supplementary Fig. S2B for representative plots; n ¼ 10 per group;  , P < 0.01, Mann–Whitney test). M, Expression of Sca (MFI) in c-KitþScaþGR-1 early
progenitors cocultured or not with NET (n¼ 10 per group;  , P < 0.01, Mann–Whitney test). N, Proliferation of CFSE-labeled FACS-sorted Lin–c-Kitþ cells to NETs in
presence ofmAbs blocking SCF-1 (ACK2) or IL6 (15A7) or isotype controls (n¼ 10 per group, excluding controls; for controls n¼ 5 per group;  , P <0.05;  , P < 0.01;
 , P < 0.001; Mann–Whitney test). O, Inhibition of NET-induced Lin–c-Kitþ cell proliferation by a speciﬁc NF-kB inhibitor (InSolution NF-kB activation inhibitor,
Calbiochem; n ¼ 6 per group;  , P < 0.01, Mann–Whitney test). NF-kB inhibition completely abrogated the NET-induced proliferation of c-Kitþ cells.
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NET formation in a proinﬂammatory bone marrow
microenvironment promotes HSC proliferation via IL6, SCF,
and NF-kB activation
TNF, IFNg (9), and complement factors (27) are major drivers
of NET formation. In a context of defective ECM molecules
(collagens and SPARC), their NET-inducing capacity increases
because of the lack of inhibitory signals that are provided by
collagens on activated PMN (5). Therefore, we investigated
whether induction of systemic autoimmunity affected NET for-
mation by bonemarrow cells. Immunizedmice showed increased
NET formation, as assessed ex vivo by measuring the capacity of
bone marrow–derived polymorphonuclear leukocytes (PMN) to
undergo spontaneous NETosis (Fig. 2H and I) as well as in situ by
immunoﬂourescence (Fig. 2J) and confocalmicroscopy (Fig. 2K).
We then investigated the capacity of NETs to affect the prolif-
eration of bone marrow hematopoietic cells. Lin–c-Kitþ (LK)
hematopoietic cells were sorted from the bone marrow, stained
with carboxyﬂuorescein succinimidyl ester (CFSE) and cocultured
with NETs in conditions enabling HSC maintenance and differ-
entiation toward myeloid lineages. As a source of NETs, we used
PMNs isolated from in vivo inﬂammatory foci that undergo
spontaneous NETosis dependent on TNF and IFNg priming
(9). In some experiments, PMA-treated NETotic PMNs were used
as positive controls (28). Starting from 72 hours of coculture,
NETotic, but not apoptotic, necrotic, or na€ve PMNs, signiﬁcantly
enhanced the proliferation of c-Kitþ bone marrow cells (Supple-
mentary Fig. S2A). An in depth analysis showed that NET specif-
ically enhanced the proliferation of c-KitþScaþGR-1– early pro-
genitors (LSK), c-KitþSca–GR-1– (LK) committed precursors
(mostly GMP), and c-KitþSca–GR-1þmyeloblasts (Fig. 2L, repre-
sentative gating strategy in Supplementary Fig. S2B). Moreover,
NETs sustained the expression of Sca-1 in c-KitþScaþGr-1– early
progenitor cells, which is crucial for HSC self-renewal and pro-
liferation (Fig. 2M).
Investigating the mechanism involved in NET-induced prolif-
eration of c-Kitþ cells, weﬁrst excluded the involvement of TLRs as
sensor of the NET DNA-backbone (Supplementary Fig. S2C and
S2D). Considering that the proliferation of c-Kitþ cells induced by
NETs was diminished, but not abrogated, by the interposition of
a transwell membrane (Supplementary Fig. S2E and S2F), we
evaluated the role of solublemediators. Stem cell factor (SCF) and
IL6 are known to promote hematopoietic cell renewal and clo-
nogenic capacity through NF-kB (29). MAbs blocking either the
IL6 receptor (15A7) or c-Kit (ACK2) strongly inhibited NET-
induced proliferation of c-Kitþ hematopoietic cells, an effect
magniﬁed by the simultaneous blockade of both receptors (Fig.
2N). Pharmacological inhibition of NF-kB had a comparable
effect (Fig. 2O), being NF-kB the main transducer of IL6R on
hematopoietic precursors (30). These data indicate that NET
inﬂammatory pressure exerted on c-Kitþ hematopoietic cells
through IL6 and SCF release confers a proliferative advantage to
hematopoietic precursors.
NET-associated immune stimulation exacerbates NPM1
mutation-driven myeloproliferation in vivo
We then investigated whether NET-induced stimulation of
hematopoietic precursors could impact on the proliferation of
myeloid cells under myeloproliferative conditions in vivo. NPMc
transgenicmice carry the humanmutatedNPMc under amyeloid-
speciﬁc promoter and are prone to develop an indolent myelo-
proliferation, in which mature myeloid cells expand without
progressing towards myelodysplasia or leukemia (31). Induction
of systemic autoimmunity in NPMc transgenic mice elicited
modiﬁcations in the bone marrow microenvironment that mir-
rored those observed in immunized WT mice (Supplementary
Figs. S3 and S4) and included in situ formation of NETs (Supple-
mentary Fig. S5A).
Compared with na€ve NPMc mice, a signiﬁcantly higher
percentage of immunized NPMc mice developed a myelopro-
liferative disorder at approximately 12 months of age (60% vs.
25%, P < 0.05). In these mice, bone marrow histopathology
revealed an exacerbated myelodysplastic/myeloproliferative
phenotype with a left-shift of myelopoiesis, clustering of atyp-
ical myeloid precursors, dysmegakaryopoiesis, and signs of
intravascular hematopoiesis (Fig. 3A). Paralleling the exacer-
bated myeloproliferation the bone marrow of immunized
NPMc mice showed a signiﬁcant difference in the density of
bone marrow erythroid colonies highlighted by TER-119
immunostaining (Fig. 3B).
Consistently, the frequency of cytoplasmic NPM-expressing
elements and of proliferating Ki67-expressing myeloid elements
in the bone marrow of immunized NPMc mice was signiﬁcantly
higher as compared with na€ve NPMc controls (Fig. 3C–E).
Moreover, bone marrow smears of immunized NPMc mice
showed an increase in immature forms of myeloid cells with
atypicalmorphology (Fig. 3F, red arrows), a concomitant decrease
in segmentedmature granulocytes (black arrows), and an increase
in lymphoid elements (green arrows). Flow cytometry analysis
of the bonemarrow showed a signiﬁcant expansion in the fraction
of hematopoetic precursors (LK and LSK) and committed
Figure 3.
NET-associated immune stimulation cooperates the with NPMc background in shaping the myeloproliferative phenotype. A, Representative bone marrow
histopathology showing hematopoietic parenchyma of WT and NPMc na€ve and immunized mice. NPMc transgenic mice exhibit myeloproliferative features with
prominent mature granulocytopoiesis. Upon immunization, the exacerbated myelopoiesis of NPMcmice becomes dysplastic with signiﬁcant left-shift of myel- and
megakaryocytopoiesis and increase in atypical myeloid precursor clusters (arrowheads, inset). Signs of intravascular hematopoiesis are evident in these
samples (dashed green line). Scale bars, 50 mm. B, IHC analysis for the erythroid Ter119 marker on bone marrow parafﬁn sections from immunized and na€ve NPMc
mice. Scale bars, 100mm. C,Representative IF analysis forNPMperformedonbonemarrow (BM)parafﬁn sections fromna€ve or immunizedWTandNPMcmice. Scale
bars, 50 mm.D,Quantitative analysis of NPM immunoﬂuorescence performed on ﬁve bone marrow sections from na€ve and immunizedNPMc orWTmice. Statistical
analysis: Student t test;  , P < 0.05. E,Quantiﬁcation of the Ki67 proliferative index in bone marrow biopsies from immunized and na€ve NPMc or WTmice (n¼ 5 per
group; statistical analysis: Student t test;  , P < 0.01; , P < 0.001). F, bone marrow smears of immunized NPMc mice showed an increase in myeloid
blasts with atypical morphology (red arrows), a concomitant decrease in segmented mature granulocytes (black arrows), and an increase in lymphoid elements
(green arrows) comparedwith na€veNPMcmice,which showed apredominance of segmentedgranulocytes and rare blasts. Scale bars, 20mm.G,BonemarrowFACS
analyses showing the total amount of Lin–c-Kitþ and LinSca1þKitþ precursor cells and myeloid progenitors (GMP) in the bone marrow of immunized NPMc mice.
The induction of megakaryocytes (Mk) and their progenitors (MkP) was also observed (n¼ 10 per group; statistical analysis: Student t test;  , P < 0.05;  , P < 0.01;
 , P < 0.001). The exacerbated myelopoiesis of immunized NPMcmice was associated with a slight but signiﬁcant decrease in B220þ lymphoid cells. H, PB FACS
analysis showing the increased percentage of the overall circulating c-Kitþ cells, myeloblasts (Gr-1þc-Kitþ and CD11bþc-Kitþ), and mature CD11bþ myeloid
cells in immunizedNPMc transgenic mice. I, Representative PB smears from na€ve and immunizedNPMcmice showing the presence of circulating atypical immature
myeloid cells in the PB of immunized but not na€ve transgenic mice. Scale bars, 20 mm.
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Figure 4.
NPMcmutation increases the proliferative response of hematopoietic precursors to NET stimulation. A, FACS-sorted Lin–c-Kitþ cells were isolated from NPMc and
WT mice, cocultured with NETs, and evaluated for proliferation in vitro. The panel shows that the NPMc mutation does not confer a cell-intrinsic proliferative
advantage to c-Kitþ cells as the proliferative response to NET is comparable in the two genotypes.B, LinSca1þKitþ cells fromNPMc andWTmicewere cocultured in
the presence or absence of NET, without other supplements, and injected intravenously into lethally irradiated WT mice. All the mice receiving LinSca1þKitþ
cocultured with NETs survived independently from the NPMc genotype of the transplanted cells. (Continued on the following page.)
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progenitors (GMP, MEP), megakaryocytes and megakaryocyte
precursors in immunizedNPMcmice. Conversely, the total num-
ber of B220þ B cells decreased (Fig. 3G; Supplementary Fig. S5B
for representative gating strategy).
Dysplastic features were also found in megakaryocytic and
granulocytic cells within extramedullary splenic hematopoietic
foci, which were expanded in immunized NPMc mice (Supple-
mentary Fig. S6A). Indeed, the frequency of cytoplasmic NPM-
expressing elements and of proliferating Ki67-expressingmyeloid
elements was increased in the spleen of immunized NPMc mice
(Supplementary Fig. S6B–S6E). Flow cytometry analysis of spleen
myeloid populations showed a signiﬁcant expansion in the
amount of LK cells and of granulocyte–monocyte progenitor
(GMP) in immunized NPMc mice (Supplementary Fig. S6F–
S6I). Finally, c-Kitþ blasts had a higher frequency in the blood
of immunized NPMcmice, a ﬁnding corroborated by the enrich-
ment inmorphologically immature circulatingmyeloid cells (Fig.
3H and I).
To provide an alternative approach testing the impact of per-
sistent immune stimulation on the take of an established acute
leukemia, we adopted the C1498 murine leukemia model (32).
C57BL/6 mice were either immunized or not with DCs loaded
with NET components and 1 month after the last immunization
they were injected intra-bone with 2  105 GFP-labeled C1498
cells. Twenty-eight days after cell injection, mice were sacriﬁced
and evaluated for the presence of C1498 in the bone marrow by
FACS. Immunization signiﬁcantly promoted the leukemic cell
take in the bonemarrowwith the increased fraction of C1498 cells
inversely correlating with that of B220þ resident cells, which were
outcompeted (Supplementary Fig. S7). These results indicate that
systemic and persistent immune activation can exacerbate the
phenotype of a genetically driven myeloproliferative spur.
NPMc mutation affects the NETosis of PMN and NET-induced
proliferation of c-Kitþ cells
Considering the data obtained in immunized NPMc mice, we
hypothesized that NETs could confer a stronger proliferative
advantage to hematopoietic precursors of NPMc rather than WT
genotype. Unexpectedly, the presence of the NPMcmutation did
not confer an intrinsic proliferative advantage to c-Kitþ cells in
response to NET stimulation (Fig. 4A). In line, LSK cells from
NPMc and WT mice cocultured with NETs in the absence of any
growth factor (i.e., SCF or IL3) were equally able to survive in
culture and to reconstitute lethally irradiated mice (Fig. 4B).
We then investigated whether bonemarrowmyeloid cells from
NPMc and WT mice were differently prone to NET formation. To
this end, bone marrow PMNs isolated from NPMc and WT mice
were seeded onto poly-D-lysine–coated slides and treated with
IFNg plus C5a or PMA. In both conditions, PMNs from NPMc
mice showed a signiﬁcantly increased NET formation in response
to inﬂammatory stimuli (Fig. 4D and E). Moreover, NETs from
NPMc mice were more efﬁcient in enhancing proliferation of c-
Kitþ cells (Fig. 4F).
As NPM may act as an alarmin and contribute to systemic
inﬂammation, for example, during sepsis (33), we hypothe-
sized that the NPMc mutation, which causes cytoplasmic
nucleophosmin localization (34), could be also responsible
for its reallocation onto NETs, thereby inﬂuencing its availabil-
ity as a NET-associated alarmin. IHC analyses performed on
bone marrow sections showed that NPM, which is almost
absent in mature bone marrow-PMNs of WT mice, is detectable
in the cytoplasm of bone marrow PMNs from NPMc mice (Fig.
4G). In these mice, immunoﬂuorescence on bone marrow
sections using an anti-NPM Ab detecting both normal and
mutated NPM, also highlighted NET threads (Fig. 4H). More-
over, at confocal microscopy, ex vivo NET from NPMc mice
displayed NPM relocalized onto the NET DNA threads (Fig. 4I),
where it associated with classical NET cytoplasmic proteins,
such as MPO (Fig. 4J).
To test the ability of extracellular NPM to act as an alarmin
for hematopoietic cells, LK cells were cultured in the presence of
recombinant human and mouse NPM. As a result, proliferation
of c-Kitþ cells exposed to extracellular NPM was signiﬁcantly
enhanced in a dose-dependent manner and this effect could be
inhibited by NF-kB blockade (Fig. 4K and L). Recombinant
NPM mimicked TNF and IFNg inﬂammatory stimuli in down-
modulating the expression of ECM molecules in bone marrow-
MSCs (Fig. 4M), a condition that promotes NET formation,
delineating a self-sustaining inﬂammatory loop in AML carry-
ing NPM1 mutation.
(Continued.) C, Neutrophils were isolated from the bone marrow of NPMc and WT mice and treated with PMA for 24 hours. Upon PMA-mediated activation,
NPMwt and NPMc PMNs exhibited a different rate of apoptosis, which was higher in the former group. D, Increased NET formation by NPMc mutant neutrophils
compared with their NPMwt counterparts in response to IFNgþC5a or PMA activation (quantiﬁcation is shown in Supplementary Fig. S10). Scale bars, 20 mm.
E, Quantiﬁcation of NET formation is shown for PMA-treated NPMc and WT neutrophils. Nuclear areas are plotted against the percentage of SYTOX-
positive cells corresponding to a given nuclear area. PMN showing an enhanced propensity to undergo NETosis display an increased frequency of nuclei with
highest nuclear areas. In this experiment, the SYTOX green DNA dye was added to PMN after PFA-ﬁxation, 18 hours later. Experiments comparing PMN from
NPMc transgenic orWTmice were repeated three times with PMN from at least three donor mice each. Number of nuclei analyzed/experiment ¼ 200 ( , P < 0,05,
Mann–Whitney t test). F, FACS-sorted Lin–c-Kitþ cells were isolated from the bone marrow of NPMc and NPMwt mice and cocultured with NETs obtained
from NPMc and NPMwt mice. The image shows that NPMc-derived NETs promoted the proliferation of c-Kitþ hematopoietic cells more efﬁciently in a 48 hours
(instead of 72 hours) assay. G, IHC for NPM was performed on bone marrow sections from NPMc and NPMwt mice. The representative image shows that, in NPMc
transgenic mice, cytoplasmic staining of NPM revealed hematopoietic myeloid cells, including mature granulocytes, scattered throughout the bone marrow
interstitium. This was not observed in the bone marrow of the NPMwtmice. Scale bars, 50 mm. H, Immunoﬂuorescence analysis of the bone marrow of NPMcmice
showing that NPM is detected in association with MP0þ DNA-thread structures suggestive of NET (arrows). Scale bars, 20 mm. I, Confocal immunoﬂuorescence
analysis for NPM performed in bone marrow neutrophils from NPMwt and NPMc mice seeded onto poly-D-lysine coated glasses and stimulated with PMA to
induce NET formation. Staining for NPM (red signal) was performed without permeabilizing cells, which allowed detection of only NPM associated with extruded
NET (highlighted by the DNA dye Sytox green, green signal) in NPMc neutrophils or apoptotic cells (arrow) in NPMwt neutrophils, but not NPM retained
within live cells. InNPMwt neutrophils, NPMwasnot detected, except in apoptotic cells (arrows). Scalebars, 10mm. J,Confocalmicroscopy analysis performedonNET
from NPMc neutrophils showing NPM colocalizing with MPO, a classical NET-associated protein, onto the DNA (Dapi staining) threads. Scale bars, 10 mm. K and L,
Proliferation of CFSE-labeled FACS-sorted Lin–c-Kitþ cells in response to recombinant murine and human NPM, with or without NF-kB inhibitor. Proliferation
was evaluated at 72 hours (n¼ 5/group;  , P < 0.01, Mann–Whitney test).M, Expression of Col1a and Sparc genes in bone marrow-MSC stimulated or not with IFNg ,
TNF, or their combination. The fold change in expression of the target genes relative to the internal control gene (GAPDH) is shown.
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Figure 5.
In situ NET detection in autoimmune and NPM1-mutated AML patients. A, IHC analysis for Foxp3 performed on one representative case of autoimmune
patient compared with healthy control. Foxp3þ Treg, arrows. Scale bars, 20 mm. B, Mean number of Foxp3þ cells in the bone marrow of autoimmune patients
(cumulative data; n ¼ 5/ﬁelds/patient; n ¼ 12/group patients). Scale bars, 20 mm. C, Immunoﬂuorescence for MPO of bone marrow sections from patients
with autoimmunity-associated cytopenias (patients #4 and #9; Supplementary Table S1) showing the presence of extracellular MPO threads, suggestive of NET
formation within the bone marrow interstitium. D, Representative immunoﬂuorescence analysis of bone marrow from a patient with autoimmunity-associated
cytopenia (patient #4, Supplementary Table S1) showing C1q complement deposition in bone marrow stromal cells and the close proximity between C1qþ stromal
elements (green) and NET MPO threads (red; arrow). Scale bars, 20 mm. E, Representative double-marker immunoﬂuorescence microphotographs of WT and
NPM1-mutated humanAMLbonemarrowbiopsies showing thepresenceof histoneH3 threads (green signal) associatedwith eitherNPM (red signal, top) orMPO(red
signal, bottom) in NET structures (arrows). NET histone H3 threads were prevalently detected in NPM1-mutated cases, in which NPM was relocalized into
the cytoplasm. Scale bars, 20 mm. F, Mean number of NETs, evaluated as MPOþ or NPMþ histone H3þ double positive threads, in bone marrow biopsies from
WT and NPM1-mutated AML (for patient details, Supplementary Table S7).
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In situNET formation canbe identiﬁed in patientswith systemic
autoimmunity and in AML patients with NPM1 mutation
To establish the translational signiﬁcance of ﬁndings in
experimental models, we performed studies in patients with
systemic autoimmunity and in myeloid malignancies. Analysis
of the bone marrow of patients with unexplained peripheral
cytopenias and signs of systemic autoimmunity (AUC; Supple-
mentary Table S1) showed mild alteration in granulocytic and
megakaryocytic differentiation that did not conﬁgure impaired
hematopoiesis or frank myelodysplasia when compared with
normal controls (not shown). No signiﬁcant differences were
found in the overall amounts of bone marrow-inﬁltrating T
cells; however, a trend towards the reduction of Foxp3þ Treg
cells was observed in the bone marrow of patients with auto-
immune disorders (Fig. 5A and B). Most importantly, in these
same patients, NETs were identiﬁed in situ by staining for MPO
and DAPI (Fig. 5C). In patients with circulating autoantibodies
(Supplementary Table S1), NET extracellular MPO threads were
associated with C1q deposition (Fig. 5D).
We then investigated thepresenceofNETs in thebonemarrowof
AML patients carrying mutations in the NPM1 gene. Immunoﬂu-
orescence analysis for the chromatinmarkerHistone-H3 and either
MPO or NPM was performed on 20 cases of AML with mutated
(N ¼ 10) or WT (N ¼ 10) NPM1. We found that, in human AML
cases, NETs were detected as Histone-H3þ threads associated with
MPO in cases in whichMPO expressionwas preserved (Fig. 5E). As
shown in transgenic NPMc mice, in the bone marrow of patients
with NPM1-mutated AML, NET ﬁgures could be identiﬁed as
characterized by the peculiar NPM localization onto the DNA
thread marked by Histone-H3 (Fig. 5E). Quantiﬁcation of NET
ﬁgures as highlighted by Histone H3 and NPM orMPO on 5 high-
power magniﬁcation microscopic ﬁelds, revealed that a higher
frequency of NET ﬁgures could be identiﬁed in NPM1 mutated
cases (Fig. 5F; Supplementary Table S2). These data suggest that
formation of NETs in the bone marrow observed in experimental
systemic autoimmunity can be also observed in spontaneously
occurring human autoimmune pathologies and occurs within the
bone marrow environment of AML with mutated NPM1.
A NET-related inﬂammatory gene signature discriminates
myeloid leukemia subsets
We then asked whether the inﬂammatory proﬁle related with
NETosis could be differently enriched at the transcriptional level
in human myeloid malignancies.
To this end, we designed an ad hoc gene signature representative
of the pathways activated in the bone marrow upon immuniza-
tion and implicated in NET induction (Supplementary Table S3;
ref. 5). The signature, thereafter referred to as NET-related inﬂam-
matory signature, was analyzed in a large panel of primary
hematopoietic malignancies, including AML (N ¼ 100), chronic
myelogenous leukemia (CML, N ¼ 50), MDS (N ¼ 50), and in
healthy bone marrow samples (N ¼ 30), obtained from a large
multicentric GEP study (see the Supplementary Information).
Unsupervised hierarchical clustering based on the expression of
the NET-related inﬂammatory signature separated AML samples
from CML, MDS, and healthy bone marrow samples (Supple-
mentary Fig. S8A). When a supervised approach was used to
identify, within theNET-related inﬂammatory signature, themost
suitable genes to differentiate the various diseases (ANOVA, P <
0.05, fold change > 2), AML was again separated from the other
samples (Supplementary Fig. S8B).
Considering the variability in the NET-related inﬂammatory
GEPs in AML, we investigated the AML cases in depth in order
to understand the contribution of inﬂammation-related genes
in this pathologic setting. We identiﬁed 20 genes (correspond-
ing to 27 probe sets) belonging to the NET-related inﬂamma-
tory signature that were differentially expressed in AML versus
healthy bone marrow samples (t-test, P < 0.05, fold change >2;
Supplementary Table S4). On the basis of the expression of
these genes, AML cases could be divided into two clusters:
cluster 1 and cluster 2 (Supplementary Fig. S8C). A supervised
analysis (t test, P < 0.05; multiple testing correction: Bonferroni
family wise error rate) was then performed to identify differ-
entially expressed genes in cluster 1 and cluster 2. We identiﬁed
592 probe sets that enabled efﬁcient discrimination between
the two clusters (Supplementary Table S5; Fig. 6A). When
studied by gene set enrichment analysis (GSEA) the corre-
sponding 440 genes turned out to be signiﬁcantly associated,
as expected, with inﬂammation and immune response pro-
grams as well as with other relevant cellular processes and
pathways, including some related with signal transduction,
hematopoietic and leukemic stemness and, most notably,
NPM1 signaling (Supplementary Table S6; Fig. 6B). This
expression pattern was not found to be related to cytogenetic
features in AML. Indeed, the two AML clusters comprised all
different karyotypic groups (Supplementary Fig. S8D). Further-
more, the 17 genes (corresponding to 25 probe sets) belonging
to the NET-related inﬂammatory signature, which were differ-
entially modulated across the cytogenetic groups, as identiﬁed
by supervised analysis (ANOVA, P < 0.05, fold change >2), were
unable to clearly discriminate between AML cases with different
karyotypic abnormalities (Supplementary Fig. S8E and S8F).
We extended the supervised analysis to an independent panel
of 461 AML cases for which gene expression data, information on
NPM1 mutational status, and clinical follow-up were available
(GEOAccess: GSE6891; ref. 23). Again, the identiﬁedNET-related
inﬂammatory signature deﬁned twoAML clusters inwhichmutat-
ed andwild-typeNPM1 caseswere signiﬁcantly segregated (c2,P <
0.001; Fig. 6C). Similar results were obtained by performing
hierarchical clustering based on the expression of the 440 genes
(Supplementary Table S5) discriminating the two AML clusters:
NPM1-mutated and NPM1-wild type cases were signiﬁcantly
divided (c2, P < 0.001; Supplementary Fig. S8G). This pattern
was independent from karyotype, in particular cases with
normal karyotype were homogeneously distributed in the two
clusters (c2, P ¼ 0.19). Consistently, we found that differen-
tially expressed genes in mutated versus wild-type NPM1 cases
were signiﬁcantly enriched in the inﬂammatory response, IFNg
response, IL6 signaling, and complement cascade programs at
gene set enrichment analysis (Supplementary Table S7). Con-
versely, when GEPs of cases presenting with somatic mutations
affecting leukemia-associated genes other than NPM1 (CEBPA,
IDH1, IDH2, KRAS, NRAS, and FLT3-ITD) were investigated,
IDH1-mutated cases were found to display signiﬁcant enrich-
ment in genes belonging to the NET-related signature, even if
only very few cases (N ¼ 3) among those of the analyzed panel
had isolated IDH1 mutations.
TheNET-related inﬂammatory gene signaturepredicts response
to immunomodulatory drugs
To assess the potential clinical impact of NET-related inﬂam-
matory features, we applied our signature to a cohort of high-risk
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Figure 6.
A NET-related inﬂammatory gene signature
subdivides acute myeloid leukemias A,
Supervised analysis of AML cases divided by
cluster (1 vs. 2) as deﬁned by the expression of
the NET-related inﬂammatory signature. The
two clusters differ in the expression of 440
genes belonging to programs of inﬂammation,
immune response, leukemic stemness, and,
notably NPM-1 signaling. In the matrix, each
column represents a sample and each row
represents a gene. The color scale bar shows the
relative gene expression changes normalized to
the standard deviation (0 is the mean
expression level of a given gene). The main
Biological Processes (GeneOntology) identiﬁed
byGSEA are highlighted on the right.B,GSEA of
the differentially expressedgenes inAML cluster
1 vs. AML cluster 2 showing the positive
enrichment of diverse inﬂammatoryprograms in
AML cluster 2. The enrichment score relative to
the different datasets is shown.
C,Hierarchical clustering of AML cases based on
the NET-related inﬂammatory signature
showing that NMP1 mutated cases were
signiﬁcantly segregated (c2, P < 0.001)
according to the signature.
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AML patients (N¼ 26; complete responders¼ 14; nonresponders
¼ 12) treated with the combination of chemotherapy and the
immunomodulatory drug lenalidomide (24). The molecular
signature associated with complete response (24) signiﬁcantly
overlapped with the NET-related inﬂammatory signature (c2, P¼
0.03), being also enriched in genes characteristic of NPM1mutat-
ed AML. In the same cohort of patients, the NET-related inﬂam-
matory signature enabled subdivision of the AML cases into two
groups with signiﬁcantly different overall survival (median esti-
mated survival 1 month vs. 20 months; 95% conﬁdence interval,
0.140–6.88/1.86–45.11 months; P < 0.001; Fig. 7A). A minimal
signature consisting of three genes (Fig. 7B) belonging to theNET-
related inﬂammatory signature, namely IRF7, C5AR1, and NF-
KBIA, were able to discriminate patients with a signiﬁcantly better
or worse outcome (P ¼ 0.03; Fig. 7C). Taken together, these data
showed that, although not associated with clinical outcome in a
cohort of AML patients treated with conventional chemotherapy,
the expression pattern of genes related with NETs was associated
with the clinical response and survival of AML patients receiving
the immunomodulatory agent lenalidomide.
Discussion
We showed that structural changes in the bone marrow stroma
are involved in shaping the myeloproliferative bone marrow
responses to systemic persistent immune stimulation. Immuni-
zation-induced autoimmunity was found to elicit downregula-
tion of SPARC and type I collagen in the bone marrow stroma as
well as to promote local inﬂammatory conditions associated with
T-cell activation and NETosis.
Within the bone marrow, NET sustained the proliferation of
hematopoietic precursors via the release of the hematopoietic
cytokines SCF and IL6 involving NF-kB.
The discovery of NET-induced expansion of hematopoietic
precursors prompted us to investigate whether the transcrip-
tional proﬁles of various human myeloid malignancies were
differently enriched in a NET-related gene signature. We found
that AML were divided into two main clusters according to the
inﬂammatory imprint. The inﬂammatory cluster segregated
according to NPM1 mutation-associated molecular programs.
The NPM1 mutation is the most frequent genetic alteration
identiﬁed in acute myeloid leukemia (AML) accounting for
Figure 7.
The NET-related inﬂammatory gene signature predicts response to immunomodulatory drugs. A, OS curves (Kaplan–Meier method) of AML patients treated
with lenalidomide plus AraC classiﬁed into two groups [group 1, complete responders (CR), blue line; group 2, nonresponders (NR), red line] based on the expression
of the entire NET-related inﬂammatory signature (support vector machine algorithm). B, Three genes belonging to the NET-related inﬂammatory signature
were found among those differentially expressed according to the clinical response (complete responders vs. nonresponders achievement) inAML patients receiving
lenalidomide plus AraC (24). C, OS curves (Kaplan–Meier method) of AML patients treated with lenalidomide plus AraC classiﬁed into two groups (group 1,
complete responders, blue line; group 2, nonresponders, red line) based on the three genes of the NET-related inﬂammatory signature (C5AR1, NFKBIA, IRF7;
support vector machine algorithm).
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about 30% of all cases. This mutation deﬁnes a subgroup of
AML with distinctive clinicopathologic features and it is also
associated with a unique GEP (18). The role of NPM1 mutation
in leukemogenesis in vivo has not been fully elucidated. The low
genetic complexity of NPM1-mutated AML suggests that this
mutation requires additional stimuli, which might also be
provided by the inﬂammatory microenvironment, to promote
malignant clone progression (18).
In this context, a large study involving 1,540patients has shown
that the impact of NPM1 mutation on transformation become
manifested only in presence of initiating mutations in epigenetic
pathways, such as in DNMT3, TET2, IDH1/2 genes (35).
This makes no surprise that in the different transgenic (31) or
conditional mousemodel (36, 37), lacking additionmutations, a
frank leukemia was rarely observed, although an indolent mye-
loproliferation, perturbed megakaryopoiesis, or MPD have been
reported. However, investigating whether an inﬂammatory bone
marrow environment was able to aggravate the indolent myelo-
proliferative phenotype of NPMc transgenic mice we found that
features of dysplastic changes and increased extramedullary
hematopoiesis were induced in NPMc immunized mice. The
NPMc mutation cooperated with NET-mediated stimulation of
c-Kitþ precursors according to the propensity of NPMc PMN to
NETosis and because of the alarmin function of the NET-com-
plexed cytoplasmic mutated NPM. This may explain, at least in
part, why theNET-related inﬂammatory signaturewas found tobe
enriched in AML with mutated NPM1. Accordingly, the mutated
NPM, although aberrantly translocated to the cytoplasm, con-
serves its functional domains, including the histone-binding
domains (38), which may explain its afﬁnity for histone-rich
NET DNA threads and its related pro-alarmin function. This
suggests thatNPMc-bearing clones may beneﬁt from the presence
of NET-triggering conditions, which may be irrelevant for clones
with t(3,5) translocation (NPM1-MLF1)or loss of chromosome5,
which result in the loss of the DNA-binding domain or in the
complete loss of NPM (39).
We discovered a novel role for NETs in stimulating hemato-
poietic precursor proliferation, also extending the inﬂuence of this
form of myeloid cell death to hematopoiesis and related disor-
ders. The identiﬁcation of AML subgroups characterized by aNET-
related inﬂammatory signature and bone marrow NET induction
claims for the investigation of immunomodulatory agent-con-
taining treatments to be adopted in combination with conven-
tional therapy in selected patients.
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